[Federal Register Volume 85, Number 24 (Wednesday, February 5, 2020)]
[Notices]
[Pages 6547-6549]
[FR Doc No: 2020-02163]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-N-4337]

Prescription Drug User Fee Act of 2017; Electronic Submissions
and Data Standards; Public Meeting; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the following public meeting entitled ``Prescription Drug User Fee Act
of 2017; Electronic Submissions and Data Standards.'' The purpose of
the public meeting and the request for comments is to fulfill FDA's
commitment to seek stakeholder input related to data standards and the
electronic submission system's past performance, future targets,
emerging industry needs, and technology initiatives. FDA will use the
information from the public meeting as well as from comments submitted
to the docket to inform data standards initiatives, FDA Information
Technology (IT) Strategic Plan, and electronic submissions gateway
target timeframes.

DATES: The public meeting will be held on April 22, 2020, from 9 a.m.
to 4 p.m. Submit either electronic or written comments on this public
meeting by April 22, 2020. See the SUPPLEMENTARY INFORMATION section
for registration date and information.

ADDRESSES: The public meeting will be held at the FDA White Oak Campus,
10903 New Hampshire Ave., Building 31 Conference Center, the Great Room
(Rm. 1503, Section A), Silver Spring, MD 20993-0002. Entrance for
public meeting participants (non-FDA employees) is through Building 1,
where routine security check procedures will be performed. For parking
and securing information, please refer to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
    You may submit comments as follows. Please note that late, untimely
filed comments will not be considered. Electronic comments must be
submitted on or before April 22, 2020. The https://www.regulations.gov
electronic filing

system will accept comments until 11:59 p.m. Eastern Time at the end of
April 22, 2020. Comments received by mail/hand delivery/courier (for
written/paper submissions) will be considered timely if they are
postmarked or the delivery service acceptance receipt is on or before
that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2018-N-4337 for ``Prescription Drug User Fee Act of 2017;
Electronic Submissions and Data Standards.'' Received comments, those
filed in a timely manner (see ADDRESSES), will be placed in the docket
and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure laws. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Chenoa Conley, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 1117, Silver Spring, MD 20993-0002, 301-
796-0035<EMAIL_ADDRESS>or Stephen Ripley, Center for
Biologics Evaluation and Research, Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002,
240-402-7911.

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is committed to achieving the long-term goal of improving the
predictability and consistency of the electronic submission process and
enhancing transparency and accountability of FDA information
technology-related activities. In the Prescription Drug User Fee Act
(PDUFA) VI commitment letter, FDA agreed to hold annual public meetings
to seek stakeholder input related to electronic submissions and data
standards to inform the FDA IT Strategic Plan and published targets.
The commitment letter outlines FDA's performance goals and procedures
under the PDUFA program for the years 2018 through 2022. The commitment
letter can be found at https://www.fda.gov/forindustry/userfees/prescriptiondruguserfee/ucm446608.htm.
    FDA will consider all comments made at this meeting or received
through the docket (see ADDRESSES).

II. Participating in the Public Meeting

    Registration: To register to attend ``Prescription Drug User Fee
Act of 2017; Electronic Submissions and Data Standards,'' please visit
the following website: https://www.eventbrite.com/e/pdufa-vi-2020-public-meeting-on-electronic-submissions-and-data-standards-tickets-73294889989. Please provide complete contact information for each
attendee, including name, title, affiliation, address, email, and
telephone. A draft agenda will be posted approximately 1 month prior to
the meeting.
    Registration is free and based on space availability, with priority
given to early registrants. Persons interested in attending this public
meeting must register by 11:59 p.m. Eastern Time on April 1, 2020.
Early registration is recommended because seating is limited;
therefore, FDA may limit the number of participants from each
organization. Registrants will receive confirmation when they have been
accepted.
    Request for Oral Presentations: During the request for comment
period, you may indicate if you wish to present at the public meeting
and which topic(s) you would like to address. FDA will do its best to
accommodate requests to make an oral presentation. Individuals and
organizations with common interests are urged to consolidate or
coordinate their presentations. Following the close of registration,
FDA will determine the amount of time allotted to each presenter and
the approximate time each oral presentation is to begin and will select
and notify participants by April 8, 2020. All requests to make oral
presentations must be received by the close of registration at 11:59
p.m. Eastern Time

on April 1, 2020. If selected for presentation, any presentation
materials must be emailed to<EMAIL_ADDRESS>no later
than April 15, 2020. No commercial or promotional material will be
permitted to be presented or distributed at the public meeting.
    Streaming Webcast of the Public Meeting: This public meeting will
also be webcast: https://collaboration.fda.gov/pdufa042220/.
    Persons attending FDA's meetings are advised that the Agency is not
responsible for providing access to electrical outlets.
    If you need special accommodations due to a disability, please
contact Chenoa Conley, (see FOR FURTHER INFORMATION CONTACT) no later
than April 1, 2020.
    Transcripts: Please be advised that as soon as a transcript of the
public meeting is available, it will accessible at https://www.regulations.gov. It may be viewed at the Dockets Management Staff
(see ADDRESSES). A link to the transcript will also be available on the
internet at https://www.fda.gov/forindustry/userfees/prescriptiondruguserfee/ucm446608.htm.

    Dated: January 29, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-02163 Filed 2-4-20; 8:45 am]
 BILLING CODE 4164-01-P